James Lomas

List of Publications by Year
in descending order

34 papers	916 citations	566801 15 h-index	500791 28 g-index
36 all docs	36 docs citations	36 times ranked	1219 citing authors

#	Article	IF	Citations
1	Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data. BMJ Global Health, 2018, 3, e000964.	2.0	181
2	A Health Opportunity Cost Threshold for Cost-Effectiveness Analysis in the United States. Annals of Internal Medicine, 2021, 174, 25-32.	2.0	103
3	Using Mobile Health Gamification to Facilitate Cognitive Behavioral Therapy Skills Practice in Child Anxiety Treatment: Open Clinical Trial. JMIR Serious Games, 2018, 6, e9.	1.7	65
4	Resolving the â€œCost-Effective but Unaffordableâ€•Paradox: Estimating the Health Opportunity Costs of Nonmarginal Budget Impacts. Value in Health, 2018, 21, 266-275.	0.1	58
5	Healthcare Cost Regressions: Going Beyond the Mean to Estimate the Full Distribution. Health Economics (United Kingdom), 2015, 24, 1192-1212.	0.8	52
6	Informing a Cost-Effectiveness Threshold for Health Technology Assessment in China: A Marginal Productivity Approach. Pharmacoeconomics, 2020, 38, 1319-1331.	1.7	48
7	Estimating the Marginal Productivity of the English National Health Service From 2003 to 2012. Value in Health, 2019, 22, 995-1002.	0.1	45
8	An Educational Review About Using Cost Data for the Purpose of Cost-Effectiveness Analysis. Pharmacoeconomics, 2019, 37, 631-643.	1.7	33
9	Is an ounce of prevention worth a pound of cure? A cross-sectional study of the impact of English public health grant on mortality and morbidity. BMJ Open, 2020, 10, e036411.	0.8	28
10	APPLYING BETAâ€TYPE SIZE DISTRIBUTIONS TO HEALTHCARE COST REGRESSIONS. Journal of Applied Econometrics, 2014, 29, 649-670.	1.3	27
11	A Quasi-Monte-Carlo Comparison of Parametric and Semiparametric Regression Methods for Heavy-tailed and Non-normal Data: an Application to Healthcare Costs. Journal of the Royal Statistical Society Series A: Statistics in Society, 2016, 179, 951-974.	0.6	25
12	The impact of NHS expenditure on health outcomes in England: Alternative approaches to identification in all-cause and disease specific models of mortality. Health Economics (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 297	0.8	24
13	Incorporating Affordability Concerns Within Cost-Effectiveness Analysis for Health Technology Assessment. Value in Health, 2019, 22, 898-905.	0.1	21
14	Accounting for Timing when Assessing Health-Related Policies. Journal of Benefit-Cost Analysis, 2019, 10, 73-105.	0.6	17
15	Valuing health outcomes: developing better defaults based on health opportunity costs. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 729-736.	0.7	16
16	Reflecting the Health Opportunity Costs of Funding Decisions Within Value Frameworks: Initial Estimates and the Need for Further Research. Clinical Therapeutics, 2020, 42, 44-59.e2.	1.1	16
17	How Effective is Marginal Healthcare Expenditure? New Evidence from England for 2003/04 to 2012/13. Applied Health Economics and Health Policy, 2021, 19, 885-903.	1.0	16
18	Empirical Estimates of the Marginal Cost of Health Produced by a Healthcare System: Methodological Considerations from Country-Level Estimates. Pharmacoeconomics, 2022, 40, 31-43.	1.7	16

#	Article	IF	Citations
19	Assessing the value of human papillomavirus vaccination in Gavi-eligible low-income and middle-income countries. BMJ Global Health, 2020, 5, e003006.	2.0	14
20	A pharmacoeconomic approach to assessing the costs and benefits of air quality interventions that improve health: a case study. BMJ Open, 2016, 6, e010686.	0.8	12
21	Economic Evaluation of Environmental Interventions: Reflections on Methodological Challenges and Developments. International Journal of Environmental Research and Public Health, 2018, 15, 2459.	1.2	12
22	Causal impact of social care, public health and healthcare expenditure on mortality in England: cross-sectional evidence for 2013/2014. BMJ Open, 2021, 11, e046417.	0.8	11
23	Cured Today, Ill Tomorrow: A Method for Including Future Unrelated Medical Costs in Economic Evaluation in England and Wales. Value in Health, 2020, 23, 1027-1033.	0.1	10
24	Avoiding Opportunity Cost Neglect in Cost-Effectiveness Analysis for Health Technology Assessment. Applied Health Economics and Health Policy, 2021, , 1.	1.0	10
25	Conducting Value for Money Analyses for Non-randomised Interventional Studies Including Service Evaluations: An Educational Review with Recommendations. Pharmacoeconomics, 2020, 38, 665-681.	1.7	9
26	Accounting for country- and time-specific values in the economic evaluation of health-related projects relevant to low- and middle-income countries. Health Policy and Planning, 2022, 37, 45-54.	1.0	8
27	The Clinical and Cost Effectiveness of Vortioxetine for the Treatment of a Major Depressive Episode in Patients With Failed Prior Antidepressant Therapy: A Critique of the Evidence. Pharmacoeconomics, 2016, 34, 901-912.	1.7	7
28	Which Costs Matter? Costs Included in Economic Evaluation and their Impact on Decision Uncertainty for Stable Coronary Artery Disease. PharmacoEconomics - Open, 2018, 2, 403-413.	0.9	7
29	Does public longâ€term care expenditure improve careâ€related quality of life of service users in England?. Health Economics (United Kingdom), 2021, 30, 2561-2581.	0.8	5
30	How Responsive is Mortality to Locally Administered Healthcare Expenditure? Estimates for England for 2014/15. Applied Health Economics and Health Policy, 2022, 20, 557-572.	1.0	5
31	Daclatasvir for the Treatment of Chronic Hepatitis C: A Critique of the Clinical and Economic Evidence. Pharmacoeconomics, 2016, 34, 981-992.	1.7	4
32	The Relevance of Including Future Healthcare Costs in Cost-Effectiveness Threshold Calculations for the UK NHS. Pharmacoeconomics, 2022, 40, 233-239.	1.7	4
33	Assessing the Impact of Health Care Expenditures on Mortality Using Cross-Country Data. World Scientific Series in Global Healthcare Economics and Public Policy, 2020, , 3-49.	0.1	3
34	Health Inequalities: To What Extent are Decision-Makers and Economic Evaluations on the Same Page? An English Case Study. Applied Health Economics and Health Policy, 2022, 20, 793-802.	1.0	3